EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

Scope & Guideline

Exploring Innovations in Mental Health Treatment

Introduction

Welcome to your portal for understanding EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1064-1297
PublisherAMER PSYCHOLOGICAL ASSOC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1993 to 2024
AbbreviationEXP CLIN PSYCHOPHARM / Exp. Clin. Psychopharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address750 FIRST ST NE, WASHINGTON, DC 20002-4242

Aims and Scopes

The journal 'Experimental and Clinical Psychopharmacology' focuses on the intricate relationships between psychopharmacological substances and their effects on behavior, cognition, and emotional processes. The journal aims to advance understanding in this field through rigorous scientific research, integrating both experimental and clinical perspectives.
  1. Psychopharmacology of Substances:
    Explores the effects of various psychoactive substances (e.g., cannabis, alcohol, opioids) on psychological and physiological functions, emphasizing their implications for mental health and addiction.
  2. Behavioral Economics and Substance Use:
    Utilizes behavioral economic frameworks to assess factors influencing substance use behaviors, including demand, decision-making processes, and the impact of socio-economic variables.
  3. Coping Mechanisms and Substance Interactions:
    Investigates how individuals cope with substance use and the interplay between different substances, including the psychological and physiological effects of co-use.
  4. Clinical Interventions and Treatment Outcomes:
    Focuses on developing and evaluating interventions for substance use disorders, including medication-assisted treatments, behavioral therapies, and harm reduction strategies.
  5. Psychometric Evaluation of Assessment Tools:
    Involves the creation and validation of scales and questionnaires aimed at measuring substance use motives, cravings, and related psychological constructs.
  6. Impact of Sociocultural Factors:
    Examines how cultural, racial, and socio-economic factors influence substance use behaviors and treatment outcomes, contributing to a more nuanced understanding of addiction.
The landscape of research within 'Experimental and Clinical Psychopharmacology' is evolving, with emerging themes that reflect current societal issues and advancements in understanding substance use. This section outlines the key areas of increasing focus.
  1. Cannabis Research and Its Effects:
    Recent publications show a significant increase in research related to cannabis, particularly its cognitive effects, therapeutic uses, and interactions with other substances, reflecting the changing legal landscape and societal interest.
  2. Impact of COVID-19 on Substance Use:
    Emerging studies are investigating how the COVID-19 pandemic has influenced patterns of substance use, highlighting the need for timely research addressing public health concerns.
  3. Diversity and Inclusion in Substance Use Research:
    There is a growing emphasis on including diverse populations in studies of substance use, particularly regarding how sociocultural factors affect treatment and outcomes.
  4. Technological Interventions for Substance Use Disorders:
    Research into digital interventions, including mobile applications and online support systems, is gaining momentum as effective tools for managing substance use and promoting recovery.
  5. Psychological Mechanisms Underlying Substance Use:
    An increasing number of studies are focusing on the psychological constructs related to substance use, such as impulsivity, anxiety sensitivity, and emotional regulation, seeking to understand their roles in addiction.

Declining or Waning

While the journal has consistently focused on various aspects of psychopharmacology and substance use, certain themes appear to be waning in prominence. This section highlights those areas that have seen a decline in research focus over recent years.
  1. Traditional Pharmacological Treatments:
    Research focusing on conventional pharmacological treatments for substance use disorders is becoming less prevalent, as newer, integrative approaches that incorporate behavioral and psychological strategies gain traction.
  2. Single-Substance Studies:
    The emphasis on studies examining the effects of single substances (e.g., alcohol or nicotine in isolation) is declining in favor of more complex investigations into multi-substance interactions and their combined effects.
  3. Longitudinal Studies on Substance Use Effects:
    Longitudinal studies investigating the long-term effects of substance use are less frequently published, suggesting a shift towards more immediate and experimental research designs.
  4. Generalized Addiction Models:
    There is a noticeable decrease in research employing broad, generalized models of addiction, with a growing focus on specific populations and contextual factors influencing substance use.

Similar Journals

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Advancing Mental Health Through Innovative Pharmacological Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Advancing the Understanding of Substance Use and Addiction
Publisher: TAYLOR & FRANCIS INCISSN: 0095-2990Frequency: 6 issues/year

American Journal of Drug and Alcohol Abuse is a highly regarded publication in the field of substance abuse research, published by Taylor & Francis Inc. With its inception in 1974, this journal has become an essential resource for scholars and practitioners interested in clinical psychology, psychiatry, and the multifaceted issues surrounding drug and alcohol use. It holds a notable Q2 ranking in Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health, emphasizing its impact and relevance in these domains. The journal's 2023 Scopus rankings further highlight its standing, placing it in the top quartile of publications with established readership and citation metrics. Researchers and students can benefit from its comprehensive articles that delve into the complexities of substance use, treatment methodologies, and the socio-psychological underpinnings of addiction. Whether you seek to access cutting-edge studies or contribute to ongoing discourse in the field, the American Journal of Drug and Alcohol Abuse serves as a vital hub for knowledge dissemination and scholarly engagement.

AMERICAN JOURNAL ON ADDICTIONS

Empowering Knowledge for a Healthier Tomorrow
Publisher: WILEYISSN: 1055-0496Frequency: 6 issues/year

The AMERICAN JOURNAL ON ADDICTIONS, published by WILEY, stands as a premier publication within the realms of Clinical Psychology, Medicine, and Psychiatry. With its ISSN 1055-0496 and E-ISSN 1521-0391, the journal has been a critical resource since its inception in 1992, consistently evolving to encompass a wide scope of addiction research and its implications on public health. Renowned for its rigorous peer-reviewed articles, it boasts impressive rankings, including Q1 status in both Clinical Psychology and Medicine (miscellaneous) for 2023, and a respectable Q2 in Psychiatry and Mental Health. As a foundational platform for disseminating cutting-edge research, the journal aims to facilitate the exchange of knowledge among researchers, healthcare professionals, and educators alike. Its significant impact on the academic community is underscored by its Scopus rankings—placing it in the top 26% of Clinical Psychology journals and the top 28% in Medicine (miscellaneous). By fostering an understanding of addiction and its treatments, the AMERICAN JOURNAL ON ADDICTIONS plays an essential role in guiding innovative practices and shaping future policies within the field.

Adicciones

Connecting insights to inspire change in addiction practices.
Publisher: SOCIDROGALCOHOLISSN: 0214-4840Frequency: 4 issues/year

Adicciones is a prominent academic journal dedicated to the fields of Medicine and Psychiatry, focusing on the multi-faceted issues surrounding addiction and substance use. Published by SOCIDROGALCOHOL in Spain, this journal has been a critical resource for researchers, clinicians, and students since its inception in 1994, with a commitment to advancing knowledge in addiction science for the benefit of public health. With an impressive impact factor that places it in the Q3 category of both Medicine (Miscellaneous) and Psychiatry and Mental Health according to 2023 rankings, Adicciones is recognized for its high-quality peer-reviewed articles that contribute to the ongoing dialogue in these vital fields. Although not currently an open-access journal, it provides valuable subscription-based access to its extensive repository of research findings and reviews, fostering a deeper understanding of the complex dynamics of addiction. The journal's continued relevance is underscored by its convergence into 2024, promising ongoing contributions that inspire new ideas and practices to combat addiction.

Journal of Addiction Medicine

Pioneering Insights into Addiction Treatment
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1932-0620Frequency: 6 issues/year

Welcome to the Journal of Addiction Medicine, a premier academic resource devoted to the field of addiction studies, published by LIPPINCOTT WILLIAMS & WILKINS. Since its inception in 2007, this esteemed journal has become a leader in disseminating groundbreaking research, with impressive rankings in the Q1 quartile across key disciplines such as Medicine (Miscellaneous), Pharmacology (Medical), and Psychiatry and Mental Health, reflecting its significance in the scholarly community. With an ISSN of 1932-0620 and an E-ISSN of 1935-3227, it caters to a diverse audience of researchers, clinicians, and students seeking to expand their understanding of addiction medicine. The journal's articles are primarily published in a non-open access format, ensuring high-quality research is accessible through institutional subscriptions. With a Scopus ranking that positions it within the top tiers of several relevant categories, the Journal of Addiction Medicine is essential for anyone committed to advancing knowledge in the field and addressing the complexities surrounding addiction.

Journal of Dual Diagnosis

Integrating care for a healthier tomorrow.
Publisher: ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTDISSN: 1550-4263Frequency: 4 issues/year

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

Activitas Nervosa Superior Rediviva

Unraveling the Complexities of the Mind and Body
Publisher: SLOVAK ACAD SCIENCES, INST NORMAL & PATHOLOGICAL PHYSIOLOGYISSN: 1337-933XFrequency: 4 issues/year

Activitas Nervosa Superior Rediviva is a peer-reviewed journal dedicated to the fields of neuropsychology, physiological psychology, psychiatry, and mental health research. Published by the esteemed SLOVAK ACADEMY OF SCIENCES, INSTITUTE OF NORMAL AND PATHOLOGICAL PHYSIOLOGY, this journal embraces an open-access model, facilitating the dissemination of critical findings and discussions within these evolving fields. With a focus on innovative studies spanning from 2009 to 2024, it provides a vital platform for researchers and professionals seeking to understand the complexities of the nervous system and related disorders. Although currently classified in the fourth quartile across relevant categories including neuropsychology and psychiatric health, the journal’s commitment to publishing quality research contributes significantly to the ongoing discourse among academics and clinicians alike. Activitas Nervosa Superior Rediviva invites scholars to engage with its content and further strengthen the integration of research and practice in mental health and neurological sciences.

Substance Abuse and Rehabilitation

Championing open access to vital addiction research.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-8467Frequency: 1 issue/year

Substance Abuse and Rehabilitation, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the study and treatment of substance abuse and related rehabilitation practices. With its ISSN 1179-8467, this journal provides a vital platform for researchers, clinicians, and students to disseminate their findings and insights in a field increasingly relevant to public health. Since becoming open access in 2010, the journal has enhanced its reach, allowing for a broader audience to engage with cutting-edge research and reviews that address the complexities of substance abuse disorders. The journal aims to foster innovation and interdisciplinary collaboration by publishing high-quality peer-reviewed articles that cover a wide range of topics, including addiction therapy, policy implications, and the social determinants of substance use. As a vital resource within the realm of addiction research, Substance Abuse and Rehabilitation plays a crucial role in driving forward knowledge and practices that can improve outcomes for individuals and communities affected by substance use issues.

ADDICTION

Connecting research with clinical excellence in addiction.
Publisher: WILEYISSN: 0965-2140Frequency: 12 issues/year

ADDICTION, published by Wiley, is a highly regarded academic journal that serves the vibrant fields of Medicine and Psychiatry and Mental Health. With an impressive impact factor reflective of its significance—ranking in the top 8% and 7.5% of its categories respectively—this journal is esteemed for its rigorous peer-reviewed research which spans a wide array of topics related to addiction, including pharmacology, prevention, and treatment modalities. Since its inception in 1993, ADDICTION has continually provided a platform for innovative research, shaping the discourse and influencing clinical practices worldwide. This journal, based in the United Kingdom at a prestigious location in Hoboken, NJ, stands as a beacon for researchers, practitioners, and students alike, committed to advancing understanding and strategies to combat addiction-related challenges. Although it is not an Open Access publication, the journal's contribution to the field remains invaluable, ensuring that cutting-edge findings are disseminated widely among professionals dedicated to improving mental health outcomes.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Elevating Clinical Insights in Pharmacology and Psychiatry
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0268-1315Frequency: 6 issues/year

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.